Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongming Pan

Showing results (211-220 of 262) with videos related to

Pageof 27
Sort By:
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Oncology|December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialAnn-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Journal of Cancer Research and Therapeutics|June 1, 2020
CSCO ablation expert workshop report: Recommendations for the management of tumor ablation during the coronavirus disease 2019 epidemicYehua Shen, Chien-Shan Cheng, Peng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic CancerShukui Qin, Jin Li, Yuxian Bai, et al.
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Pageof 27

Showing results (211-220 of 262) with videos related to

Sort By:
Pageof 27
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Oncology|December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialAnn-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Journal of Cancer Research and Therapeutics|June 1, 2020
CSCO ablation expert workshop report: Recommendations for the management of tumor ablation during the coronavirus disease 2019 epidemicYehua Shen, Chien-Shan Cheng, Peng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic CancerShukui Qin, Jin Li, Yuxian Bai, et al.
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Pageof 27